Asko Therapeutics, Inc.
Publicly observedAnn Arbor, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Ann Arbor | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Asko Therapeutics, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | HXZAWBGUS6X6 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Aug 2025Publicly observed
NIH SBIR/STTR award: Novel injectable implants for long-term local controlled release of therapeutic monoclonal antibodies
USD 350,027.00 · National Institute of General Medical Sciences · Source: NIH RePORTER (opens in a new tab)
- Grant18 Jul 2025Publicly observed
NIH SBIR/STTR award: Paradigm-changing, versatile, scalable and cost-effective technology for monthly injections of peptide drugs
USD 350,027.00 · National Institute of General Medical Sciences · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.